论文部分内容阅读
S.S.M.是从人型结核杆菌提取的多糖物质,又称“丸山疫苗”。作为抗肿瘤药物,在日本已对20多万肿瘤病人进行了试验性治疗,对肺癌与乳腺癌有一定疗效。其抗瘤机制与刺激淋巴细胞和巨噬细胞引起胶原增生有关。我们用反向溶血空斑试验检测了S.S.M对正常人的体外抗体形成应答的影响,因为此应答可综合的反映淋巴细胞与单核—巨噬细胞的功能。由于正常人细胞对PWM反应产生PFC的数量个体差异很大,按一般文献,我们用个人的细胞在加S.S.
S.S.M. is a polysaccharide material extracted from human Mycobacterium tuberculosis, also known as “Maruyama vaccine.” As an anti-tumor drug, it has undergone experimental treatment for more than 200,000 cancer patients in Japan, and it has a certain effect on lung cancer and breast cancer. Its anti-tumor mechanism is associated with stimulation of lymphocyte and macrophage-induced collagen hyperplasia. We used the reverse hemolytic plaque assay to examine the effect of S.S.M on the in vitro antibody-forming response of normal humans because this response can comprehensively reflect the function of lymphocytes and monocytes-macrophages. Since the number of PFCs generated by normal human cells in the PWM response varies widely, we use the individual cells in the S.S.